- Home
- DOUG vs DERM Comparison
DOUG vs DERM Comparison
Compare DOUG & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- DERM
- Stock Information
- Founded
- DOUG 1911
- DERM 2014
- Country
- DOUG United States
- DERM United States
- Employees
- DOUG N/A
- DERM N/A
- Industry
- DOUG Building operators
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- DERM Health Care
- Exchange
- DOUG Nasdaq
- DERM Nasdaq
- Market Cap
- DOUG 219.1M
- DERM 213.6M
- IPO Year
- DOUG N/A
- DERM 2021
- Fundamental
- Price
- DOUG $2.45
- DERM $7.59
- Analyst Decision
- DOUG
- DERM Strong Buy
- Analyst Count
- DOUG 0
- DERM 3
- Target Price
- DOUG N/A
- DERM $12.67
- AVG Volume (30 Days)
- DOUG 351.4K
- DERM 247.9K
- Earning Date
- DOUG 11-04-2025
- DERM 11-12-2025
- Dividend Yield
- DOUG N/A
- DERM N/A
- EPS Growth
- DOUG N/A
- DERM N/A
- EPS
- DOUG N/A
- DERM N/A
- Revenue
- DOUG $1,030,928,000.00
- DERM $59,399,000.00
- Revenue This Year
- DOUG $17.61
- DERM $26.16
- Revenue Next Year
- DOUG N/A
- DERM $45.27
- P/E Ratio
- DOUG N/A
- DERM N/A
- Revenue Growth
- DOUG 6.67
- DERM 2.82
- 52 Week Low
- DOUG $1.48
- DERM $3.54
- 52 Week High
- DOUG $3.20
- DERM $9.40
- Technical
- Relative Strength Index (RSI)
- DOUG 47.12
- DERM 45.63
- Support Level
- DOUG $2.34
- DERM $7.27
- Resistance Level
- DOUG $2.48
- DERM $8.18
- Average True Range (ATR)
- DOUG 0.12
- DERM 0.48
- MACD
- DOUG -0.01
- DERM -0.16
- Stochastic Oscillator
- DOUG 45.45
- DERM 19.94
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.